---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-011212"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:39:12.386855+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CervoMed posts 2023 net loss of $2.2M; secures $50M private placement; Phase 2b DLB trial on track

## Summary
- Net loss $2.2M for 2023; cash $7.8M as of Dec 31, 2023; R&D spending increased to $8.4M.
- Private placement of $50M upfront (up to $149.4M with warrants) led by RA Capital; expected to fund through end of 2025.
- RewinD-LB Phase 2b enrollment on track to complete Q2 2024; topline data expected Q4 2024.
- Appointed Joshua Boger, founder of Vertex Pharmaceuticals, as non-executive Chair of the Board.

## SEC filing metadata
- accession: 0001437749-24-011212
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924011212/0001437749-24-011212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924011212/crvo20240405_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-011212
- JSON: https://secwatch.observer/filing/0001437749-24-011212.json
- Plain text: https://secwatch.observer/filing/0001437749-24-011212.txt

## Key facts
- Earnings Releases
  CervoMed Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774924011212/0001437749-24-011212-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.